A Phase 1 Clinical Trial of a Human Chimeric Anti-Activated DC Antibody to Prevent AGVHD in high risk allo HSCT.

Funded Activity Summary

Bone Marrow transplants provide life saving therapy for leukaemias, lymphomas and other life threatening blood disorders. One of the major life threatening complications is acute graft versus host disease (AGVHD) in which the doner immune system damages the patient's skin, liver and gut, amongst other tissues. Dendritic cells initiate and direct immune responses. We have shown that dendritic cells are central to the initiation of AGVHD and have shown that a marker called CMRF-44 is expressed on activated dendritic cells before AGVHD emerges. We have developed potential new therapeutic antibodies that target activated dendritic cells and shown that they are effective in preclinical studies. This project will further validate these antibodies, then test their safety and their ability to prevent AGVHD in patients. The trial will also test whether they have the expected additional beneficial effect of preserving protective anti-viral and anti leukaemic immune responses.

Funded Activity Details

Start Date: 01-01-2007

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $670,736.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Haematology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Acute Graft Versus Host Disease | Allogeneic Haematopoietic Stem Cell Transplants | Bone Marrow Transplantation | Dendritic Cell Therapy | Graft versus host disease | High Risk Allogeneic Haematopoietic Transplantation | Human Chimeric Antibodies | Leukemia

Related Links